Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, and The Medicines Company (Nasdaq: MDCO), a global
biopharmaceutical company focused on hospital care, announced today that
Alnylam has initiated a Phase 1 clinical trial with ALN-PCSsc, an
investigational agent for the treatment of hypercholesterolemia.
for Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks